S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
PRLD · Prelude Therapeutics Incorporated
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Prelude Therapeutics Inc (PRLD)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$3.65
+0.13
(+3.69%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$3.65
$3.56
$3.69
52-WEEK RANGE
$3.65
$1.16
$6.83
What's happening
- PRLD is up 3.69% today, trading at $3.65. — Live quote
- Volume today (78,247) is well below its 3-month average of 512,340. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.14 actual vs. $-0.20 estimated (+30.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 7
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (11 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
PRLD
+21.72%
vs S&P 500
+8.95%
1-YEAR RETURN
PRLD
+173.64%
vs S&P 500
+159.08%
6-MONTH RETURN
PRLD
-20.32%
3-MONTH RETURN
PRLD
-12.62%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.14
Est. $-0.20
BEAT +30.2%
2026-04-26 (Q1 2026)
$-0.13
Est. $-0.25
BEAT +48.7%
2026-01-26 (Q4 2025)
$-0.20
Est. $-0.03
MISS -575.7%
2025-10-26 (Q3 2025)
$-0.26
Est. $-0.37
BEAT +30.2%
Valuation Measures & Ratios
Enterprise Value4$258.6M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)12.71
Price / Book73.17
EV4 / Revenue11.53
EV4 / EBITDA—
Profit Margin-269.75%
Operating Margin-300.56%
Return on Equity (ROE8)-75.35%
Return on Assets (ROA9)-44.39%
Avg Volume (3M)512,340
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $528.5M | $271.6M | $109.2M | $59.8M | $59.3M |
| P/E | -7.02 | -2.91 | -0.95 | -0.46 | -0.45 |
| Price/Sales | 31.49 | 24.51 | 11.50 | — | — |
| Price/Book | 3.95 | 4.51 | 1.87 | 0.79 | 0.57 |
| EV/Revenue | 29.92 | 22.55 | 6.50 | — | — |
| EV/EBITDA | -6.23 | -2.51 | -0.51 | — | — |
| ROE | -56.28% | -155.24% | -197.00% | -171.85% | -126.51% |
| ROA | -39.74% | -78.09% | -121.69% | -113.41% | -92.40% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short4,575,044
Change from Prior Settlement+26.15%
% of Float—
Days to Cover (Short Ratio)7.91
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 41.0% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +173.6%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -269.8%. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-09-10; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on PRLD
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.7M | $4.6M | $6.5M | $0 | $0 | $3.0M | — | — |
| Operating income | -$15.5M | -$14.2M | -$20.4M | -$32.2M | -$34.6M | -$34.4M | -$37.2M | -$34.3M |
| Net income | -$13.9M | -$10.4M | -$19.7M | -$31.2M | -$32.1M | -$32.3M | -$34.7M | -$31.4M |
| EPS (diluted) | $-0.14 | $-0.13 | $-0.26 | $-0.41 | $-0.42 | $-0.43 | $-0.46 | $-0.42 |
| EPS (basic) | $-0.14 | $-0.13 | $-0.26 | $-0.41 | $-0.42 | $-0.43 | $-0.46 | $-0.42 |
| Operating margin | -$271 | -$310 | -$314 | — | — | -$1.1K | — | — |
| Net margin | -$244 | -$227 | -$303 | — | — | -$1.1K | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $189.4M | $119.6M | $141.3M | $94.8M | $114.9M | $141.3M | $175.5M | $197.2M |
| Total liabilities | $55.6M | $59.5M | $72.7M | $36.2M | $39.1M | $38.1M | $44.1M | $40.8M |
| Stockholders' equity | $133.7M | $60.2M | $68.6M | $58.5M | $75.8M | $103.2M | $131.5M | $156.4M |
| Total current assets | $154.9M | $84.6M | $105.7M | $58.3M | $76.9M | $102.4M | $135.9M | $156.4M |
| Total current liabilities | $38.0M | $41.7M | $53.0M | $18.2M | $20.9M | $19.8M | $25.6M | $22.2M |
| Cash & equivalents | $26.3M | $21.8M | $35.3M | $47.5M | $25.8M | $40.3M | $12.5M | $11.1M |
| Marketable securities (current) | $125.4M | $59.8M | $68.0M | $7.4M | $47.5M | $58.8M | $121.1M | $142.5M |
| Property, plant & equipment | $4.4M | $4.7M | $5.1M | $5.5M | $6.0M | $6.4M | $6.8M | $7.2M |
| Accounts payable | $2.0M | $2.1M | $4.0M | $2.5M | $5.0M | $5.8M | $7.7M | $5.9M |
| Accrued liabilities | $8.0M | $5.9M | $12.5M | $12.9M | $13.2M | $11.3M | $15.2M | $13.6M |
| Deferred revenue (current) | $25.2M | $31.0M | $33.7M | — | — | — | $0 | — |
| Other non-current liabilities | $2.7M | $2.8M | $2.8M | $2.9M | $3.0M | $3.0M | $3.1M | $3.2M |
| Retained earnings | -$707.4M | -$693.4M | -$683.1M | -$666.6M | -$646.9M | -$615.6M | -$583.6M | -$554.8M |
| Accumulated other comprehensive income (loss) | -$227.0K | -$41.0K | $8.0K | $2.0K | -$1.0K | $12.0K | $35.0K | $167.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.6M | -$21.7M | $23.1M | -$19.1M | -$26.1M | -$34.2M | -$20.7M | -$27.3M |
| Investing cash flow | -$65.5M | $8.5M | -$60.3M | $40.1M | $11.5M | $62.2M | $22.1M | $10.7M |
| Financing cash flow | $85.8M | -$314.0K | $24.9M | -$5.0K | $37.0K | -$160.0K | -$34.0K | -$131.0K |
| Free cash flow | -$15.6M | -$21.7M | $23.1M | -$19.1M | -$26.1M | -$34.3M | -$20.8M | -$27.4M |
| Capital expenditures | $0 | $0 | $0 | $0 | $20.0K | $47.0K | $53.0K | $63.0K |
| Depreciation & amortization | $353.0K | $391.0K | $418.0K | $425.0K | $433.0K | $435.0K | $489.0K | $405.0K |
| Share-based compensation | $2.0M | $2.0M | $1.8M | $2.4M | $3.8M | $3.8M | $3.8M | $5.9M |
| Change in accounts payable | -$154.0K | -$1.9M | $1.3M | -$2.4M | -$850.0K | -$1.9M | $1.8M | -$213.0K |
| Purchases of investments | $90.0M | $0 | $66.7M | $0 | $24.7M | $9.5M | $7.3M | $32.0M |
| Tax withholding on stock comp | $13.0K | $51.0K | $5.0K | $5.0K | $2.0K | $5.0K | $7.0K | $13.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $12.1M | $7.0M | — | — | — |
| Operating income | -$104.6M | -$139.7M | -$132.3M | -$123.5M | -$113.7M |
| Net income | -$99.5M | -$127.2M | -$121.8M | -$115.4M | -$111.7M |
| EPS (diluted) | $-1.29 | $-1.68 | $-2.02 | $-2.44 | $-2.43 |
| EPS (basic) | $-1.29 | $-1.68 | $-2.02 | $-2.44 | $-2.43 |
| Operating margin | -$861 | -$2.0K | — | — | — |
| Net margin | -$820 | -$1.8K | — | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $141.3M | $175.5M | $277.7M | $220.5M | $305.1M |
| Total liabilities | $72.7M | $44.1M | $40.6M | $25.1M | $19.2M |
| Stockholders' equity | $68.6M | $131.5M | $237.1M | $195.4M | $285.9M |
| Total current assets | $105.7M | $135.9M | $235.6M | $204.4M | $295.1M |
| Total current liabilities | $53.0M | $25.6M | $21.8M | $21.7M | $19.2M |
| Cash & equivalents | $35.3M | $12.5M | $25.3M | $30.6M | $31.8M |
| Marketable securities (current) | $68.0M | $121.1M | $207.6M | $171.1M | $259.4M |
| Property, plant & equipment | $5.1M | $6.8M | $7.3M | $4.9M | $3.9M |
| Accounts payable | $4.0M | $7.7M | $4.6M | $6.8M | $7.8M |
| Accrued liabilities | $12.5M | $15.2M | $15.8M | $13.1M | $9.6M |
| Deferred revenue (current) | $33.7M | $0 | — | — | — |
| Other non-current liabilities | $2.8M | $3.1M | $3.3M | $3.4M | $0 |
| Retained earnings | -$683.1M | -$583.6M | -$456.4M | -$334.6M | -$219.1M |
| Accumulated other comprehensive income (loss) | $8.0K | $35.0K | $223.0K | -$1.7M | -$711.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$56.3M | -$102.9M | -$107.1M | -$83.7M | -$83.5M |
| Investing cash flow | $53.5M | $90.2M | -$34.6M | $81.7M | -$263.8M |
| Financing cash flow | $24.8M | -$120.0K | $136.4M | $815.0K | $164.9M |
| Free cash flow | -$56.4M | -$103.7M | -$110.6M | -$86.7M | -$85.9M |
| Capital expenditures | $67.0K | $764.0K | $3.5M | $3.0M | $2.3M |
| Depreciation & amortization | $1.7M | $1.8M | $1.2M | $1.3M | $915.0K |
| Share-based compensation | $11.9M | $21.3M | $25.6M | $25.1M | $20.9M |
| Change in accounts payable | -$3.9M | $3.3M | -$2.3M | -$347.0K | $3.9M |
| Purchases of investments | $100.9M | $52.7M | $221.6M | $119.2M | $261.5M |
| Tax withholding on stock comp | $17.0K | $54.0K | $17.0K | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding PRLD as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-07-04 to 2026-04-27
Recent transactions
- Most recent: RA CAPITAL MANAGEMENT, L.P. (Reporting person) — Other acquisition/disposition of 1,407,000 shares on 2026-04-27.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Reporting person | Other acquisition/disposition | 2026-04-27 | 1,407,000 |
| Bonita David P | Director | Open market purchase | 2026-04-21 | 1,689,189 |
| ORBIMED ADVISORS LLC | Director | Open market purchase | 2026-04-21 | 1,689,189 |
| Huang Jane | President, CMO | Option exercise | 2025-10-04 | 9,375 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-04-27 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Other acquisition/disposition | 1,407,000 | — |
| 2026-04-21 | Bonita David P | Director | Open market purchase | 1,689,189 | $4.44 |
| 2026-04-21 | Bonita David P | Director | Open market purchase | 1,126,126 | $4.44 |
| 2026-04-21 | ORBIMED ADVISORS LLC | Director | Open market purchase | 1,689,189 | $4.44 |
| 2026-04-21 | ORBIMED ADVISORS LLC | Director | Open market purchase | 1,126,126 | $4.44 |
| 2025-10-04 | Huang Jane | President, CMO | Option exercise | 9,375 | — |
| 2025-10-04 | Huang Jane | President, CMO | Tax withholding | 3,355 | $1.47 |
| 2025-07-04 | Huang Jane | President, CMO | Option exercise | 9,375 | — |
| 2025-07-04 | Huang Jane | President, CMO | Tax withholding | 3,355 | $0.79 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:17 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-10 | 8-K | 2026-09-10 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-06-10 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-10 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-10 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-10 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-10 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-10 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-10 | 8-K | 2026-06-09 | View on SEC.gov → |
| 2026-05-12 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-12 | 8-K | 2026-05-12 | View on SEC.gov → |
Recent news
Headlines about PRLD (Prelude Therapeutics Incorporated). Links open the publisher — we don’t host full articles.
-
Prelude Therapeutics secures Lilly deal. Citizens targets Prelude Therapeutics stock at USD 6.00
AD HOC NEWS · 2026-10-20 -
Prelude Therapeutics at Chardan conference: bet on selective degraders By Investing.com
Investing.com Nigeria · 2026-10-20 -
Prelude Therapeutics to Participate in the Chardan Healthcare Conference
Yahoo · 2026-10-16 -
Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround
Yahoo · 2026-10-16 -
Eli Lilly (LLY) Reported One Year Steroid Free Control In Difficult IBD
Yahoo · 2026-10-15 -
Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial
Yahoo · 2026-10-13 -
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
Yahoo · 2026-10-13 -
Prelude Therapeutics Enters Clinical Trial Collaboration And Supply Agreement With Eli Lilly For Supply Of Its CDK4/6 Kinase Inhibitor, Abemaciclib And Its Oral Estrogen Receptor Antagonist Imlunestrant
Benzinga · 2026-10-13
No headlines in this category right now — try “All”.